interactive web-based response system (Cenduit GmbH)
90
Structured Review
Cenduit GmbH
interactive web-based response system
Interactive Web Based Response System, supplied by Cenduit GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+interactive+response+system/interactive+web+based+response+system/pmc11585249-53-5-9
Average 90 stars, based on 1 article reviews
Interactive Web Based Response System, supplied by Cenduit GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+interactive+response+system/interactive+web+based+response+system/pmc11585249-53-5-9
Average 90 stars, based on 1 article reviews
interactive web-based response system - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217. Article Snippet: Patients were randomized via an Article Title: Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial. Article Snippet: After a screening period of up to 4 weeks, participants were randomized to 24 weeks of double- blind treatment with Article Title: Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. Article Snippet: Published Online xxx https://doi.org/10.. 1016/j.ebiom.2023.. 104923 Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial Nicholas C. Cullen, Petr Novak,b,∗ Duygu Tosun, Branislav Kovacech, Jozef Hanes, Eva Kontsekova, Michal Fresser, Stefan Ropele, Howard H. Feldman, Reinhold Schmidt, Bengt Winblad, and Norbert Zilka Article Title: Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 Article Snippet: Patients were randomized via an Article Title: Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study Article Snippet: Background Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in menopausal women as options are scarce for those who cannot or do not want to take hormone therapy.. Fezolinetant is one of the first non-hormonal neurokinin 3 receptor antagonists in development for the treatment of vasomotor symptoms due to menopause.. This study investigated the safety and efficacy of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Article Title: Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial Article Snippet: After a screening period of up to 4 weeks, participants were randomized to 24 weeks of double‐blind treatment with opicapone 50 mg or matched placebo using an Article Title: Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. Article Snippet: Eligible patients were randomly allocated (1:1) centrally using an interactive web response system (IWRS, Article Title: Combination therapy Article Snippet: Randomisation and Masking Patients were randomly assigned in a 1:1 ratio either to the early |